Answers are grounded in this paper and cite their sources.
Myelofibrosis (MF) is the clinically most severe subcategory of myeloproliferative neoplasms (MPN), which can present as primary MF (PMF), or develop from the progression of polycythemia vera (PV) and essential thrombocythemia (ET; post-PV MF [PPV-MF] or post-ET MF [PET-MF]) [ 1 ]. Prominent clinical features in MF include bone marrow fibrous tissue hyperplasia, anemia, splenomegaly, and constitutional symptoms [ 1 ]. Patients with intermediate-2 risk and high-risk MF harbor a poor prognosis, and allogeneic hematopoietic stem cell transplant (allo-HSCT) currently remains the only curative treatment in MF, but allo-HSCT-related complications might result in death or substantial morbidity.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: